Integration in classic psychedelic-assisted therapies for mental health conditions: a scoping review
Psychedelics July 1, 2026 Nicholas Vucak, Raimondo Bruno, Julio Quealy et al.
Psychedelic integration—the process of making sense of and incorporating a psychedelic experience into daily life—is a core component of psychedelic-assisted therapy but is poorly defined and reported in clinical research. A scoping review of 44 articles (30 clinical trials, 8 protocols, 6 manuals) found psilocybin was the most studied classic psychedelic. Among trials reporting integration, 1–4 sessions were provided per dose (median 2), each lasting 1–3 hours (median 1.5). The first session typically occurred 24–48 hours post-dose, with a second about a week later. Reporting of session content, therapeutic conduct, and facilitator training was minimal, especially outside psilocybin trials. The authors argue that standardized, transparent reporting is needed to improve safety and enable cross-trial comparisons.